BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Career Advice

  Webinar: Breaking into Biotech

  This webinar will help you discover effective strategies for launching your career in biotechnology. You will gain valuable insights from industry experts and leave with the essential tools you need to thrive in this dynamic field.

  October 29, 2024

   · 

  1 min read

   · 

  BioSpace Insights
• 

  Inflammatory bowel disease

  Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024

  Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease following approvals for ulcerative colitis. GlobalData projects total sales for Tremfya to reach $7.8 billion globally by 2029.

  October 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  WuXi AppTec Remains Resilient Amid Threat from BIOSECURE Act, Continues to Attract New Clients

  As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new customers in the first nine months of 2024, while being hit with a 2% revenue decline in the third quarter.

  October 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure

  CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.

  October 29, 2024

   · 

  2 min read

   · 

  Greg Slabodkin
• 

  Policy

  Harris vs. Trump: How Will the Presidential Election Impact Biopharma?

  While some analysts say Donald Trump is a wild card when it comes to drug pricing, many argue his presidency would be more positive for the industry overall, as Kamala Harris has her price-cutting sights squarely on Big Pharma.

  October 29, 2024

   · 

  7 min read

   · 

  Greg Slabodkin
• 

  Earnings

  Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints

  Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.

  October 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

  October 29, 2024

   · 

  4 min read
• Press Releases

  Vesalius Cardiovascular Announces Clinical Advisory Board

  October 29, 2024

   · 

  3 min read
• Press Releases

  Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

  October 29, 2024

   · 

  4 min read
• Press Releases

  BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

  October 29, 2024

   · 

  4 min read